Guidant's cardiac rhythm management sales up 18%
This article was originally published in Clinica
In the first results since its initial public offering last December, Guidant has reported strong sales growth of its cardiac rhythm management (CRM) products. These rose 18% in the fourth quarter compared with a year earlier. Guidant points out that operating expenses rose just 1% in the fourth quarter and CEO Ronald Dollens considers this reflects Guidant's initial success at cost control.